Subcutaneous Teriparatide for Pelvic Fracture Healing: A Phase 2 Randomized Controlled Trial
Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.Osteoporos Int. 2022 Jan;33(1): 239-250.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Thirty-five patients over the age of 50 with an acute pelvic fracture were randomized to receive 3 months of subcutaneous teriparatide injections (n=18) or placebo injections (n=17). Outcomes of interest included pain scores on a Numeric Rating Scale (NRS), physical performance scores (Continuous Summary Physical Performance Score [CSPPS]; timed up and go), and bone healing. Results revealed no si...
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.Continue